Bramox® tablets are licensed for use in adult patients with severe orthostatic hypotension due to autonomic dysfunction when corrective factors have been ruled out and other forms of treatment are inadequate.

Bramox® tablets contain midodrine hydrochloride and are available in two strengths: 2.5 mg and 5 mg.

Midodrine has been used in the UK on an unlicensed basis since the late 1990s. Midodrine has been approved since 2002 or earlier in many other countries including France, Germany, Spain, Ireland, Italy, the Netherlands, Spain, USA and Canada, but it remained unlicensed in the UK until the approval of Bramox® in March 2015.

Bramox® is the first and only pharmaceutical treatment approved for the treatment of severe orthostatic hypotension due to autonomic dysfunction in the UK.

Now that Bramox® is licensed for use in the UK, unlicensed supplies of midodrine no longer need to be used. Bramox® (midodrine) can be ordered as set out here.

Prescribe and dispense Bramox® to:

    • Guarantee patients receive MHRA licensed midodrine
    • Continue to realise a ~60% saving vs. the historic cost of unlicensed midodrine in primary care¹
    • Remove liability for unlicensed drug use from healthcare professionals
    • Ensure a high quality regulated product, with consistent MA approved English language labelling

1. NHS PCA data England 2014, NHS PCA data Wales 2014